Security Snapshot

Omega Therapeutics, Inc. - COMMON STOCK (OMGAQ) Institutional Ownership

CUSIP: 68217N105

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.02

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Shares outstanding
55,351,475
SEC-reported price per share
$0.02
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • OMGAQ - Omega Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 68217N105.
  • Latest finished 13F holder period is not available.
  • 2 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
  • SEC-reported value moved from $16,199 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

68217N105

Latest holder period

n/a

13F holders

13D/G owners

2

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
2
Security
OMGAQ
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Flagship V VentureLabs Rx Fund, L.P. 53% 0% $1,461,279 -$336,554 29,225,579 0% Noubar Afeyan 03 Feb 2025
Flagship Ventures Fund V, L.P. 53% $1,461,279 29,225,579 Noubar Afeyan 29 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
18
Latest
n/a
Rows shown
1-18 of 18
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$16,199 $0.02 0
2025 Q3 13,278 $16,199 +$16,199 $1.22 1
2025 Q2 0 $0 -$2,426 $0.02 0
2025 Q1 19,648 $2,426 -$35,238,961 $0.08 3
2024 Q4 47,281,697 $35,253,886 -$921,856 $0.75 50
2024 Q3 48,290,202 $58,913,912 -$6,029,323 $1.22 51
2024 Q2 50,536,326 $104,609,269 -$2,392,066 $2.07 66
2024 Q1 51,125,783 $186,608,609 +$3,748,687 $3.65 67
2023 Q4 50,206,798 $151,122,782 +$1,376,674 $3.01 62
2023 Q3 50,887,878 $109,409,866 -$615,060 $2.15 56
2023 Q2 51,093,635 $286,122,600 +$4,687,211 $5.60 58
2023 Q1 50,231,941 $302,897,871 +$25,616,806 $6.03 54
2022 Q4 16,768,091 $95,744,501 +$387,343 $5.71 46
2022 Q3 42,604,506 $230,915,000 +$907,410 $5.42 40
2022 Q2 42,484,051 $161,436,866 -$5,642,349 $3.80 44
2022 Q1 43,545,600 $271,743,574 +$3,782,679 $6.24 50
2021 Q4 42,043,809 $475,104,000 +$9,664,162 $11.33 43
2021 Q3 14,966,151 $277,952,000 +$277,952,000 $18.85 40
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .